Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test

European Journal of Pharmacology

Volumn 557, Issue 2-3, 2007, Pages 154-158

  Suzuki, Masanori ^a   Noguchi, Yukiko ^a   Okutsu, Hiroko ^a   Ohtake, Akiyoshi ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antimuscarinic drug; Darifenacin; Learning; Oxybutynin; Passive avoidance task; Propiverine; Solifenacin; Tolterodine

Indexed keywords

DARIFENACIN; DONEPEZIL; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SCOPOLAMINE BROMIDE; SOLIFENACIN; TOLTERODINE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; LATENT PERIOD; LEARNING; LEARNING DISORDER; MALE; NONHUMAN; OVERACTIVE BLADDER; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT;

ANIMALS; AVOIDANCE LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LEARNING; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, WISTAR; URINARY BLADDER, OVERACTIVE;

EID: 33846612758     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.054     Document Type: Article

References (25)

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., and Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am. J. Obstet. Gynecol. 187 (2002) 116-126
2. Blokkand A. Acetylcholine: a neurotransmitter for learning and memory. Brain Res. Rev. 21 (1996) 285-300
3. Caulfield M.P., and Birdsall N.J. International Union of Pharmacology. XVII. 1998. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50 (1998) 279-290
4. Chapple C.R., et al., for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. 48 (2005) 464-470
5. Eglen R.M., Hegde S.S., and Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48 (1996) 531-565
6. Ehlert F.J., Ostrom R.S., and Sawyer G.W. Subtypes of the muscarinic receptor in smooth muscle. Life Sci. 61 (1997) 1729-1740
7. Homma Y., et al., on behalf of the Japanese and Korean tolterodine study group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 92 (2003) 741-747
8. Isomae K., Morimoto S., Hasegawa H., Morita K., and Kamei J. Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur. J. Pharmacol. 465 (2003) 97-103
9. Jewart R.D., Green J., Lu C.J., Cellar J., and Tune L.E. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am. J. Geriatr. Psychiatry 13 (2005) 324-328
10. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., and D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 46 (1998) 8-13
11. Lipton R.B., Kolodner K., and Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol. 173 (2005) 493-498
12. Lu C.J., and Tune L.E. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am. J. Geriatr. Psychiatry 11 (2003) 458-461
13. MacDiarmid S.A., Anderson R.U., Armstrong R.B., and Dmochowski R.R. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J. Urol. 174 (2005) 1301-1305
14. Madersbacher H., Voigt A., and Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 84 (1999) 646-651
15. Matsui M., Yamada S., Oki T., Manabe T., Taketo M.M., and Ehlert F.J. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci. 75 (2004) 2971-2981
16. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., and Sasamata M. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 492 (2004) 243-250
17. Ohtake, A., Saitoh, C., Yuyama, H., Ukai, M., Okutsu, H., Noguchi, Y., Hatanaka, T., Suzuki, M., Sato, S., Sasamata, M., Miyata, K., in press. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol. Pharm. Bull.
18. Ohtake A., Sato S., Ikeda K., Sasamata M., and Miyata K. Pharmacological and clinical profile of solifenacin succinate (Vesicare®) developed as a new therapeutic agent for overactive bladder. Folia Pharmacol. Jpn. 128 (2006) 425-432
19. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin. Ther. 27 (2005) 144-153
20. Siegler E.L., and Reidenberg M.R. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin. Pharmacol. Ther. 75 (2004) 484-488
21. Sugiyama T., Park Y.C., and Kuriya T. Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol. Res. 27 (1999) 393-395
22. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 41 (2001) 636-644
23. Tokita K., Yamazaki S., Yamazaki M., Matsuoka N., and Mutoh S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol. Biochem. Behav. 73 (2002) 511-519
24. Tsao J.W., and Heilman K.M. Transient memory impairment and hallucinations associated with tolterodine use. New Engl. J. Med. 349 (2003) 2274-2275
25. Womack K.B., Kenneth M., and Heilman M. Tolterodine and memory. Dry but forgetful. Arch. Neurol. 60 (2003) 771-773